Vor Biopharma Inc.

NasdaqGS:VOR Stock Report

Market Cap: US$845.3m

Vor Biopharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:VOR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Dec 25BuyUS$34,999,988Forbion Capital Partners B.V.Company3,237,742US$10.81
30 Oct 25SellUS$10,368,938RA Capital Management, L.P.Company400,408US$28.18
27 Oct 25SellUS$6,204,863RA Capital Management, L.P.Company221,166US$28.12
21 Oct 25SellUS$1,133,103Reid HoffmanIndividual37,533US$31.00
21 Oct 25SellUS$3,433,992RA Capital Management, L.P.Company117,050US$30.12
17 Oct 25SellUS$13,706,609RA Capital Management, L.P.Company464,001US$31.17
16 Oct 25SellUS$2,348,744Reid HoffmanIndividual73,676US$32.77
16 Oct 25SellUS$752RA Capital Management, L.P.Company24US$31.35
14 Oct 25SellUS$3,003,706Reid HoffmanIndividual96,657US$33.09
09 Oct 25SellUS$4,116,369Reid HoffmanIndividual124,146US$34.34
07 Oct 25SellUS$3,553,499Reid HoffmanIndividual98,387US$37.77
03 Oct 25SellUS$1,646,237Reid HoffmanIndividual41,752US$42.32
16 Sep 25SellUS$688,853Reid HoffmanIndividual22,363.9US$30.80
15 Sep 25SellUS$1,703,971Reid HoffmanIndividual49,240.25US$36.62
11 Sep 25SellUS$521,421Reid HoffmanIndividual14,240.25US$36.62
10 Sep 25SellUS$2,457,975Reid HoffmanIndividual63,182.35US$40.01
05 Sep 25SellUS$2,767,982Reid HoffmanIndividual70,381.4US$39.92
28 Aug 25SellUS$2,848,511Reid HoffmanIndividual70,899.9US$40.23
26 Aug 25SellUS$1,411,083Reid HoffmanIndividual33,576.8US$42.33
08 Jul 25SellUS$4,763,3915AM Venture Management, LLCCompany96,943US$49.14

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VOR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,184,7012.19%
VC/PE Firms13,226,04024.4%
Institutions18,631,12034.4%
General Public21,143,72139%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 768%.

Top Shareholders

Top 25 shareholders own 59.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.5%
TCG Crossover Management, LLC
5,673,078US$88.5m0%2.49%
7.26%
RA Capital Management, L.P.
3,935,608US$61.4m-27.2%0.65%
6.68%
Forbion Capital Partners B.V.
3,617,354US$56.4m853%8.2%
4.69%
Frazier Life Sciences Management, LP
2,543,939US$39.7m0%1.01%
4.66%
FMR LLC
2,526,170US$39.4m968%no data
3.69%
Qiming Weichuang Venture Capital Management (Shanghai) Company Limited
1,999,939US$31.2m4,800%1.55%
3.59%
VR Management, LLC
1,943,766US$30.3m289%0.95%
3.23%
Paradigm Biocapital Advisors LP
1,750,000US$27.3m0%0.61%
2.53%
Great Point Partners, LLC
1,370,107US$21.4m0%5.84%
2.15%
Reid Hoffman
1,166,909US$18.2m-28.8%no data
1.85%
Nextbio Capital Management Lp
999,967US$15.6m0%8.11%
1.71%
Caligan Partners, LP
925,067US$14.4m0%1.23%
1.42%
The Vanguard Group, Inc.
770,250US$12.0m632%no data
0.86%
BlackRock, Inc.
465,636US$7.3m1,250%no data
0.8%
Citadel Advisors LLC
433,894US$6.8m7,530%no data
0.76%
Sphera Funds Management Ltd
410,417US$6.4m0%0.93%
0.59%
Laurion Capital Management LP
317,243US$4.9m0%0.39%
0.54%
UBS Asset Management AG
292,118US$4.6m285%no data
0.43%
Findell Capital Management LLC
231,000US$3.6m0%1.3%
0.41%
Millennium Management LLC
224,534US$3.5m807%no data
0.34%
Geode Capital Management, LLC
185,808US$2.9m578%no data
0.31%
Tudor Investment Corporation
167,673US$2.6m0%0.02%
0.3%
Columbia Management Investment Advisers, LLC
163,061US$2.5m0%no data
0.27%
The Goldman Sachs Group, Inc.
145,640US$2.3m2,710%no data
0.18%
Logos Global Management, L.P.
100,000US$1.6m0%0.09%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/16 22:33
End of Day Share Price 2026/04/16 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vor Biopharma Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Carter GouldBarclays
Justin WalshB. Riley Securities, Inc.